Innovations in Cancer Sample Preparation

The summary for the Innovations in Cancer Sample Preparation grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Innovations in Cancer Sample Preparation: The National Cancer Institute (NCI) invites applications for research projects involving the development and significant enhancement or adaptation of sample preparation methodologies and technologies, the development of assays to assess sample quality, and studies designed to elucidate the criteria by which to judge sample quality. The outcome will be products and methods designed to optimize sample utility. Samples may originate from residual material not necessary for patient care or from cell lines, model organisms, or other sources relevant to cancer research. The development of new and/or improved cancer sample preparation methodologies and technologies, the development of assays to assess sample quality, and studies to elucidate the criteria needed to judge sample quality covers a wide range of project sizes and innovation levels. This RFA will allow the submission of applications involving R21, R21/R33, and R33 mechanisms. R21 applicants may propose small, highly innovative feasibility studies or small, short-term exploratory studies to meet one of the RFA goals. R21/R33 applicants should propose projects that require a small feasibility study followed by a well-defined development plan. Successful completion of the R21 feasibility study and the resulting transition to the R33 phase will be judged by NCI staff per NCI R21/R33 policy. Projects for which feasibility has already been established may be proposed as R33 applications. Feasibility means that some preliminary experiments have been performed and that there is sufficient technical data to support proof-of- principle of the technology/hypothesis. This initiative is part of a broader technology development program within the NCI. That program underscores the desire of NCI to develop and integrate novel technologies focused on the molecular analysis of cancers and their micro-environment in support of cancer research, diagnosis, and treatment. In the research continuum of discovery, development, and delivery, this program thus emphasizes the link between development and delivery. This specific initiative aims to foster the development of sample preparation techniques and methodologies that are essential for effective research, technology development, and validation that will eventually lead to clinical applications. This RFA capitalizes on both the success and intent of the original NCI sponsored Innovative Molecular Analysis Technologies (IMAT) program in bringing together a multi-disciplinary group of scientists and engineers to work on cancer and the expansion of interest in technology development across the NCI and other NIH institutes. This continuation of the IMAT program consists of the following three initiatives: Innovative Technologies for the Molecular Analysis of Cancer; Innovations in Cancer Sample Preparation; and Application of Emerging Technologies for Cancer Research. This RFA is designed to support research focused on sample preparation methods. Projects focused on the development of novel technologies may be most suitable for RFA CA-05-002, Innovative Technologies for the Molecular Analysis of Cancer (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-002.html). Projects focused on evaluating emerging technologies that are ready for initial clinical or biological application in cancer research may be most suitable for RFA CA-05-003, Application of Emerging Technologies for Cancer Research (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-003.html). Applicants from small businesses are encouraged to submit applications to the parallel RFA for each IMAT initiative, which utilizes the SBIR and STTR grant mechanisms (see MECHANISMS OF SUPPORT).
Federal Grant Title: Innovations in Cancer Sample Preparation
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-05-004
Type of Funding: Grant
CFDA Numbers: 93.39293.393
CFDA Descriptions: Cancer Construction 93.393 Cancer Cause and Prevention Research
Current Application Deadline: No deadline provided
Original Application Deadline: February 17, 2004; June 17, 2004; October 18, 2004
Posted Date: Dec 23, 2003
Creation Date: Dec 23, 2003
Archive Date: Nov 17, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.394 -- Cancer Detection and Diagnosis Research
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
More Grants from the National Institutes of Health
Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K0...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinica...
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com